Sentiment-Signal
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
HOCH Abgang Schlüsselpersonen (13.02.2026)
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 13.02.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 12.06.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co |
Stammdaten
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Zenas BioPharma, Inc. was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is based in Waltham, Massachusetts.
Unternehmen & Branche
| Name | Zenas BioPharma, Inc. |
|---|---|
| Ticker | ZBIO |
| CIK | 0001953926 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 784,8 Mio. USD |
| Beta | -0,51 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 10,000,000 | -377,737,000 | -8.44 | 383,640,000 | 242,144,000 |
| 2025-09-30 | 10-Q | 0 | -51,499,000 | -1.22 | 322,018,000 | 196,428,000 |
| 2025-06-30 | 10-Q | 0 | -52,223,000 | -1.25 | 293,085,000 | 239,626,000 |
| 2025-03-31 | 10-Q | 10,000,000 | -33,573,000 | -0.80 | 333,766,000 | 284,317,000 |
| 2024-12-31 | 10-K | 5,000,000 | -156,988,000 | -11.89 | 369,968,000 | 312,458,000 |
| 2024-09-30 | 10-Q | 0 | -38,606,000 | -5.02 | 403,432,000 | 359,435,000 |
| 2024-06-30 | 10-Q | 0 | -37,977,000 | -24.23 | -288,782,000 | |
| 2024-03-31 | 10-Q | -27,800,000 | -17.89 | -252,495,000 | ||
| 2023-12-31 | 10-K | 50,000,000 | -37,124,000 | -24.25 | 68,180,000 | -225,721,000 |
| 2023-09-30 | 10-Q | 50,000,000 | 35,608,000 | 1.96 | -202,232,000 | |
| 2023-06-30 | 10-Q | -29,047,000 | -238,853,000 | |||
| 2023-03-31 | 10-Q | -19,098,000 | -210,646,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-29 | MOULDER LEON O JR | Director, Officer, Chief Executive Officer | Open Market Purchase | 35,000 | 17.62 | 616,700.00 | +75,5% | |
| 2026-04-28 | MOULDER LEON O JR | Director, Officer, Chief Executive Officer | Open Market Purchase | 25,000 | 18.02 | 450,500.00 | +55,2% | |
| 2026-03-31 | Lu Hongbo | Director | Open Market Purchase | 3,768 | 18.63 | 70,197.84 | +8,6% | |
| 2026-03-31 | MOULDER LEON O JR | Director, Officer, Chief Executive Officer | Open Market Purchase | 34,000 | 19.31 | 656,540.00 | +80,4% | |
| 2026-03-30 | MOULDER LEON O JR | Director, Officer, Chief Executive Officer | Open Market Purchase | 20,000 | 18.23 | 364,600.00 | +44,7% | |
| 2026-02-13 | Allen Patricia L | Director | Open Market Purchase | 4,160 | 26.36 | 109,657.60 | +13,4% | |
| 2026-02-12 | Allen Patricia L | Director | Open Market Purchase | 5,000 | 26.50 | 132,500.00 | +16,2% | |
| 2026-02-12 | Allen Patricia L | Director | Open Market Purchase | 5,700 | 24.34 | 138,738.00 | +17,0% | |
| 2026-02-12 | Allen Patricia L | Director | Open Market Purchase | 5,000 | 23.77 | 118,850.00 | +14,6% | |
| 2026-02-11 | Lu Hongbo | Director | Open Market Purchase | 25,985 | 22.50 | 584,662.50 | +71,6% | |
| 2026-02-02 | MOULDER LEON O JR | Director, Officer, Chief Executive Officer | Open Market Purchase | 57,000 | 17.96 | 1,023,720.00 | +125,4% | |
| 2026-01-09 | MOULDER LEON O JR | Director, Officer, Chief Executive Officer | Open Market Purchase | 20,000 | 16.55 | 331,000.00 | +40,5% | |
| 2026-01-08 | MOULDER LEON O JR | Director, Officer, Chief Executive Officer | Open Market Purchase | 30,000 | 16.30 | 489,000.00 | +59,9% | |
| 2026-01-07 | MOULDER LEON O JR | Director, Officer, Chief Executive Officer | Open Market Purchase | 50,000 | 16.38 | 819,000.00 | +100,3% | |
| 2025-10-09 | SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner | Open Market Purchase | 63,158 | 19.00 | 1,200,002.00 | +147,0% | |
| 2025-10-09 | ENRIGHT PATRICK G | Director | Open Market Purchase | 105,265 | 19.00 | 2,000,035.00 | +245,0% | |
| 2025-10-09 | ENRIGHT PATRICK G | Director | Open Market Purchase | 11,990 | 20.85 | 249,991.50 | +30,6% | |
| 2025-10-09 | SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner | Open Market Purchase | 63,157 | 19.00 | 1,199,983.00 | +147,0% | |
| 2025-10-07 | Lu Hongbo | Director | Open Market Purchase | 263,160 | 19.00 | 5,000,040.00 | +612,5% | |
| 2025-10-07 | MOULDER LEON O JR | Director, Officer, See Remarks | Open Market Purchase | 36,928 | 20.85 | 769,948.80 | +94,3% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.